Femasys, Inc. (FEMY)
NASDAQ:FEMY
Want to see FEMY full AI Analyst Report?
FEMY Stock Chart & Stats
$0.73
-$0.01(-0.91%)
At close: 4:00 PM EST
$0.73
-$0.01(-0.91%)
Day’s Range― - ―
52-Week Range$0.31 - $1.11
Previous CloseN/A
Volume25.00K
Average Volume (3M)946.36K
Market Cap
$26.45M
Enterprise Value$12.24M
Total Cash (Recent Filing)$5.39M
Total Debt (Recent Filing)$4.73M
Price to Earnings (P/E)21.3
Beta0.76
Next Earnings
Aug 12, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding60,390,686
10 Day Avg. Volume2,014,766
30 Day Avg. Volume946,362
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.88
Price to Sales (P/S)9.94
P/FCF Ratio-1.19
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue5.15
Enterprise Value/Gross Profit9.69
Enterprise Value/Ebitda-0.83
Forecast
1Y Price Target
$1.50Price Target Upside105.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$3.77M
Bulls Say, Bears Say
Bulls Say
Revenue Growth / Commercial TractionConsistent multi-year revenue growth indicates early commercial adoption of FemVue and related consumables. Sustained top-line expansion supports a path to scale in fertility diagnostics, improving the odds that fixed costs can be absorbed and unit economics will strengthen as market penetration widens.
Strong Gross MarginsMid-to-high gross margins signal favorable unit economics for the company’s device and consumable business. If revenues continue to grow, these margins support operating leverage and the potential to narrow losses without relying solely on pricing or cost cuts, a durable advantage in med‑tech distribution.
Operational & Regulatory PositioningAdding an experienced medical-device COO and highlighting scalable U.S. manufacturing plus regulatory clearances materially strengthens commercialization capabilities. Improved operations, manufacturing control and regulatory coverage are structural enablers of sustainable market expansion and faster adoption by clinicians.
Bears Say
Severe Cash BurnLarge, persistent negative operating and free cash flow indicate the business is not yet self‑funding and will require external capital to sustain operations. This structural cash burn limits strategic flexibility, burdens management with financing priorities, and raises funding risk over the next several quarters.
Very Large Losses / Unscaled Cost BaseExtremely negative operating and net margins reflect a cost structure far outpacing revenue. Unless revenue growth accelerates materially, continued high SG&A/R&D relative to sales will suppress returns and make profitability distant, leaving long-term investor outcomes dependent on sustained adoption.
Reliance On Dilutive Financing & Lender InfluenceRecent approvals to enable reverse splits, convertible issuance and warrants plus lender representation on the board signal structural dependence on dilutive financing. Ongoing capital raises may dilute equity and lender influence can constrain strategic choices, posing governance and funding risks.
Femasys News
FEMY FAQ
What was Femasys, Inc.’s price range in the past 12 months?
Femasys, Inc. lowest stock price was $0.31 and its highest was $1.11 in the past 12 months.
What is Femasys, Inc.’s market cap?
Femasys, Inc.’s market cap is $26.45M.
When is Femasys, Inc.’s upcoming earnings report date?
Femasys, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 79 days.
How were Femasys, Inc.’s earnings last quarter?
Currently, no data Available
Is Femasys, Inc. overvalued?
According to Wall Street analysts Femasys, Inc.’s price is currently Undervalued.
Does Femasys, Inc. pay dividends?
Femasys, Inc. does not currently pay dividends.
What is Femasys, Inc.’s EPS estimate?
Femasys, Inc.’s EPS estimate is -0.06.
How many shares outstanding does Femasys, Inc. have?
Femasys, Inc. has 60,390,686 shares outstanding.
What happened to Femasys, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Femasys, Inc.?
Currently, no hedge funds are holding shares in FEMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Femasys, Inc.
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
FEMY Stock 12 Month Forecast
Average Price Target
$1.50
▲(105.48% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
NexGel Inc
―
―
Ownership Overview
3.01% Insiders
2.50% Mutual Funds
11.06% Other Institutional Investors
81.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---